0

Production of a Mouse Monoclonal IgM Antibody That Targets the Carbohydrate Thomsen-nouveau Cancer Antigen Resulting in in Vivo and in Vitro Tumor Killing

Kevin R Trabbic, Kristopher A Kleski, Mengchao Shi, Jean-Paul Bourgault, Jillian M Prendergast, Daniel T Dransfield, Peter R Andreana

Cancer Immunol Immunother. 2018 Sep;67(9):1437-1447.

PMID: 30030557

Abstract:

The construction of a tumor-associated carbohydrate antigen-zwitterionic polysaccharide conjugate, Thomsen-nouveau-polysaccharide A1 (Tn-PS A1, where Tn = D-GalpNAc), has led to the development of a carbohydrate binding monoclonal antibody named Kt-IgM-8. Kt-IgM-8 was produced via hybridoma from Tn-PS A1 hyperimmunized Jackson Laboratory C57BL/6 mice, splenocytes and the murine myeloma cell line Sp2/0Ag14 with subsequent cloning on methyl cellulose semi-solid media. This in-house generated monoclonal antibody negates binding influenced from peptides, proteins, and lipids and preferentially binds monovalent Tn antigen as noted by ELISA, FACS, and glycan array technologies. Kt-IgM-8 demonstrated in vitro and in vivo tumor killing against the Michigan Cancer Foundation breast cell line 7 (MCF-7). In vitro tumor killing was observed using an LDH assay that measured antibody-induced complement-dependent cytotoxicity and these results were validated in an in vivo passive immunotherapy approach using an MCF-7 cell line-derived xenograft model. Kt-IgM-8 is effective in killing tumor cells at 30% cytotoxicity, and furthermore, it demonstrated approximately 40% reduction in tumor growth in the MCF-7 model.

Chemicals Related in the Paper:

Catalog Number Product Name Structure CAS Number Price
IAR4246100 Monoclonal Anti-Gemin 8 antibody produced in mouse Monoclonal Anti-Gemin 8 antibody produced in mouse Price
qrcode